Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473589 · ClinicalTrials.gov registry record · Phase 3
Effect of Teriparatide on Hip Fracture Healing
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT01473589 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 122 participants.
The verdict
NCT01473589, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age with a recent hip (femoral neck) fracture caused by low-trauma (for example, fall from standing height or less).
Interventions
- DRUG Placebo
- DRUG Teriparatide
- DIETARY_SUPPLEMENT Vitamin D supplementation
- DIETARY_SUPPLEMENT Calcium supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473589
The ClinicalTrials.gov registry entry for NCT01473589 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01473589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473589 about?
NCT01473589 is a clinical study titled "Effect of Teriparatide on Hip Fracture Healing". The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age...
What is the current status of trial NCT01473589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2012-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01473589?
The interventions under investigation include: Placebo (DRUG), Teriparatide (DRUG), Vitamin D supplementation (DIETARY_SUPPLEMENT), Calcium supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01473589?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.